Reprint
Killing Cancer
Discovery and Selection of New Target Molecules
Edited by
November 2020
302 pages
- ISBN978-3-03943-440-4 (Hardback)
- ISBN978-3-03943-441-1 (PDF)
This book is a reprint of the Special Issue Killing Cancer: Discovery and Selection of New Target Molecules that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
Despite the efficiency of current cancer treatments, cancer is still a deadly disease for too many. In 2008, 7.6 million people died of cancer; with the current development, it is estimated that the annual cancer death number will grow to 13 million by 2030. There is clearly a need for not only more research but also more innovative and out of the mainstream scientific ideas to discover and develop even better cancer treatments. This book presents the collective works published in the recent Special Issue entitled “Killing Cancer: Discovery and Selection of New Target Molecules”. These articles comprise a selection of studies, ideas, and opinions that aim to facilitate knowledge, thoughts, and discussion about which biological and molecular mechanisms in cancer we should target and how we should target them.
Format
- Hardback
License and Copyright
© 2021 by the authors; CC BY license
Keywords
ferlin; myoferlin; dysferlin; otoferlin; C2 domain; plasma membrane; sulconazole; NF-κB; IL-8; mammosphere; breast cancer stem cells; AF1Q; MLLT11; WNT; STAT; esophageal cancer; prognosis; mTORC1; mTORC2; metabolism; rapalogs; mTOR inhibitors; cancer metabolism; mTOR in immunotherapy; nutrient metabolism; kinase inhibitors; mTOR signaling; MAPK kinase; ERK1; ERK2; CD domain; Rolled; SCH772984; VRT-11E; sevenmaker; cancer therapy; EMT; lysosome; lysosome-mediated invasion; MZF1; phosphorylation; PAK4; SUMOylation; transcription factor; zinc finger; glucocorticoids; 3D growth; nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB); epithelial–mesenchymal transition; anoikis; proliferation; targeted cancer therapy; disulfiram; NPL4; replication stress; DNA damage; BRCA1; BRCA2; ATR pathway; PDAC; TCIRG1; ATP6V0a3; invasion; migration; matrix degradation; proliferation; pH-regulation; autophagy; multidrug resistance in cancer; drug efflux pumps; ATP-binding cassette transporter; breast cancer resistance protein (BCRP); ABCG2; pyrazolo-pyrimidine derivative; SCO-201; colorectal cancer; immunotherapy; inflammation; microsatellite instability; oncofetal chondroitin sulfate; chondroitin sulfate; cancer; solid tumors; target; pediatric cancer; VAR2; dexamethasone; thyroid cancer; microgravity; space environment; n/a; n/a; n/a